logo

For the Inventor, By the Inventor

Yardley, PA, United States of America

B Richard Vogt

USPTO Granted Patents = 54

Average Co-Inventor Count = 1.7

ph-index = 8

Forward Citations = 290(Granted Patents)

Forward Citations (Not Self Cited) = 279(Dec 10, 2025)


Inventors with similar research interests:


Company Filing History:

goldMedal54 out of 1,624 
 
E. R. Squibb Sons, Inc.
 patents

Years Active: 1976-1984

Loading Chart...
Areas of Expertise:
Enkephalinase Inhibitors
Steroid Derivatives
Pyrazoloquinazoline Derivatives
Triazolo Benzodiazepines
Anti-Inflammatory Compounds
Benzisothiazole Derivatives
Radiolabeling Techniques
Psychotropic Treatments
Heterocyclic Compounds
Asthma Treatment
Radioimmunoassays
Triazole Derivatives
54 patents (USPTO):Explore Patents
1. 4474799 - Enkephalinase inhibitors (1984-10-02),
2. 4474795 - Enkephalinase inhibitors (1984-10-02),
3. 4401677 - Enkephalinase inhibitors (1983-08-30),
4. 4345096 - Steroid derivatives and their use in radioimmunoassays (1982-08-17),
5. 4337255 - Pyrazolo[1,5-c]quinazoline derivatives and related compounds (1982-06-29),
6. 4282226 - Thioxopyrazolo[1,5-c]quinazoline derivatives, anti-allergic compositions (1981-08-04),
7. 4248783 - Steroids having a 3-(4-hydroxyphenyl)pentanedioic acid monohydrazide (1981-02-03),
8. 4243608 - 3-(4-Hydroxyphenyl)pentanedioic acid, monohydrazide, derivatives and (1981-01-06),
9. 4239896 - 5-(Optionally substituted 2-aminophenyl)-1H-pyrazole-3-methanol (1980-12-16),
10. 4230621 - Steroid derivatives and their use in radioimmunoassays (1980-10-28),
11. 4221725 - Steroid derivatives and their use in radioimmunoassays (1980-09-09),
12. 4213982 - Novel 4H-S-triazolo[4,3-A] [1,5]benzodiazepin-5-ones (1980-07-22),
13. 4209614 - Vitamin B.sub.12 derivative suitable for radiolabeling (1980-06-24),
14. 4198412 - Pyrazolo [1,5-C] quinazoline derivatives and their use in treating (1980-04-15),
15. 4179561 - Method for making pyrazolo[1,5-c]quinazoline derivatives and related (1979-12-18),

Title: B Richard Vogt: Innovator in Enkephalinase Inhibition

Introduction: B Richard Vogt, based in Yardley, PA, has made significant contributions to the field of biochemistry through his innovative work. With an impressive portfolio of 54 patents, Vogt has established himself as a leading figure in the development of enkephalinase inhibitors, which play a critical role in regulating pain and other physiological functions.

Latest Patents: Vogt's latest patents focus on the inhibition of enkephalins' degradation in mammalian hosts. These patents describe the administration of enkephalinase enzyme inhibitors using specific chemical formulas that are geared towards enhancing therapeutic outcomes for various ailments related to pain management.

Career Highlights: Throughout his career, B Richard Vogt has been associated with E.R. Squibb & Sons, Inc., where he has significantly contributed to the advancement of pharmacological research. His innovative mind and persistent dedication have led to numerous breakthroughs in the understanding and application of enkephalinase inhibitors.

Collaborations: Vogt has collaborated with notable colleagues, including Peter C. Wade and Jack Bernstein. Their collective expertise has fostered an environment of innovation, leading to valuable contributions to the pharmaceutical industry.

Conclusion: B Richard Vogt's impact on the field of enkephalinase inhibitors exemplifies the importance of innovation and collaboration in scientific research. His extensive patent portfolio not only highlights his creativity but also his commitment to advancing medical science for the benefit of society.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…